Regenerative medicine in spine surgery is on the rise, and there are many biologic tools that physicians say could be used more in the field.
Biologics
Temple Therapeutics, a women's health company, launched a spinoff venture for orthopedic sports medicine, according to a Sept. 9 news release.
Growing biologics portfolios will play a key role in pushing the spine surgery device market in the coming years, according to a report from Coherent Market Insights.
From product debuts and approvals, here are four key updates from orthobiologic companies since June 4.
LifeNet Health, in partnership with Johnson & Johnson MedTech, launched the PliaFX Pak bone allograft in the U.S., according to an Aug. 27 news release shared with Becker's.
Elutia, formerly Aziyo Biologics, has continued to face litigation related to spine biologics allegedly linked to tuberculosis infections that were recalled in recent years.
One of 10 former MiMedx employees involved in a noncompete lawsuit has filed counterclaims against the company.
Vericel earned FDA approval for a supplemental Biologics License Application, which will expand the company's Maci label to include arthroscopy, according to an Aug. 26 news release.
SurGenTec earned FDA 510(k) clearance for its B-Man bone marrow aspirate kit, according to an Aug. 23 news release.
Ossium Health's OssiGraft Prime was used in its first successful case, the orthobiologic company said July 30.
